Clinical trials: Obstructive Lung Disease
Asthma
FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects
The purpose of this study is to address an Food Drug and Administration (FDA) request to provide safety data in pre-asthmatic patients, ages 6 months to <12 months, following administration of fluticasone propionate HFA.
- Trial name
- NCT00370097
- Testing
- FLOVENT (fluticasone propionate) HFA
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Mild to Moderate Bronchial Asthma
Safety and Efficacy of SA09012 in Asthma
Clinical Study to Evaluate the Efficacy, Dose-response and Safety of SA09012 in Bronchial Asthma Patients
- Trial name
- NCT01740986
- Testing
- SA09012 Low dose, SA09012 High dose
- Where
- 14 sites in South Korea
- Volunteers
- 225 people
- Sponsor
- SamA Pharmaceutical Co., Ltd
Asthma
Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101)
The aim of this study is to compare the responsiveness of lower airways in adult patients with stable asthma after treatment with ciclesonide and fluticasone propionate.
- Trial name
- NCT00306163
- Testing
- Ciclesonide, Fluticasone
- Where
- Netherlands
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Acute Upper Respiratory Infection, Acute Bronchitis
Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase)
A phase 4 study to evaluate efficacy and safety of MUCOLASE tablet (streptokinase • streptodornase)
- Trial name
- NCT04252963
- Testing
- MUCOLASE tablet (streptokinase • streptodornase)
- Where
- South Korea
- Volunteers
- 346 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Pulmonary Disease, Chronic Obstructive
Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients
The objective of the trial is to compare the lung function profile of once daily treatment with tiotropium+olodaterol FDC [2.5/ 5µg and 5/ 5µg] delivered by the RESPIMAT with the lung function profile of twice daily treatment…
- Trial name
- NCT01969721
- Testing
- fluticasone propionate, salmeterol, tiotropium
- Where
- 29 sites in Belgium, Czechia and 6 more
- Volunteers
- 229 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)
This study is being conducted to determine if the co-administration of formoterol fumarate and tiotropium bromide is more effective than the use of tiotropium bromide alone in patients with COPD.
- Trial name
- NCT00139932
- Testing
- formoterol fumarate
- Volunteers
- 255 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Disease, Chronic Obstructive
Effects of Salmeterol on Autonomic Nervous System
This is a 4-week non-randomized, partially blinded, single-arm monocentre study in subjects with Chronic Obstructive Pulmonary Disease (COPD) Global Initiative for Chronic Obstructive Lung Disease (GOLD) class II or III with the…
- Trial name
- ESAN (NCT01536587)
- Testing
- Salmeterol
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Asthma
Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily
To evaluate the efficacy, dose response and safety of four doses of GSK2190915 in tablet form (10mg, 30mg, 100mg and 300mg) administered once daily, over 8 weeks compared with placebo in adolescent and adult subjects (12 years of…
- Trial name
- NCT01147744
- Testing
- Fluticasone Propionate 100mcg via ACCUHALER/DISKUS, GSK2190915 100mg, GSK2190915 10mg
- Where
- 84 sites in United States, Bulgaria and 4 more
- Volunteers
- 700 people
- Sponsor
- GlaxoSmithKline
Asthma
First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic Participants
This is a 3-part, parallel group treatment, Phase 1, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetics after sequential single and multiple ascending doses of SAR443765 in…
- Trial name
- NCT05366764
- Testing
- SAR443765, Salbutamol or levosalbutamol
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The aim of the present study is to evaluate the effect of aclidinium bromide 400 μg twice a day (BID) administered twice a day versus placebo on exercise endurance and on hyperinflation and dyspnoea at rest and during exercise…
- Trial name
- NCT01471171
- Testing
- Aclidinium Bromide
- Where
- 14 sites in Germany, Spain and 1 more
- Volunteers
- 112 people
- Sponsor
- AstraZeneca
Asthma
Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients
This is a comparator study to assess safety and efficacy of Flutiform compared with Fluticasone pMDI and Seretide pMDI in paediatric asthma patients with moderate to severe persistent, reversible asthma.
- Trial name
- NCT01511367
- Testing
- Flutiform, Seretide, Flixotide
- Where
- 8 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 498 people
- Sponsor
- Mundipharma Research Limited
Asthma
Bronchial Ablation for Treatment of Asthma (BATA) Trial
To evaluate the safety and efficacy of a bronchial radiofrequency ablation system (SyMap Medical (Suzhou) Ltd) in a population of subjects with severe asthma who are still symptomatic despite being managed on high-dose Inhaled…
- Trial name
- BATA (NCT03765307)
- Testing
- SyMap Bronchial Ablation System, Boston Scientific Alair System
- Where
- 15 sites in China
- Volunteers
- 160 people
- Sponsor
- SyMap Medical (Suzhou), Ltd.
Asthma
Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 y) (BY9010/M1-145)
The aim of the present study is to investigate the efficacy and safety of ciclesonide on lung function and safety. Ciclesonide will be inhaled at one dose level once daily, using an inhaler device with or without spacer.
- Trial name
- NCT00163436
- Testing
- Ciclesonide
- Where
- 66 sites in Canada, France and 4 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
COPD
Clinical Efficacy and Cost Effectiveness of MYCOPD in Patients With Mild and Moderate Newly Diagnosed COPD
Millions of patients in the UK live with long term medical conditions such as diabetes, heart disease and lung diseases. These conditions are the major cause of ill health in the UK and cost the NHS billions of pounds each year.
- Trial name
- EARLY (NCT03620630)
- Testing
- myCOPD
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- my mhealth Ltd
Asthma
SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363)
The purpose of this study is to assess the treatment effect of montelukast 10mg on the primary endpoint of Asthma Control Questionnaire(ACQ), over a 8-week period, in persistent asthma patients with or without allergic rhinitis.
- Trial name
- STAR (NCT00445107)
- Testing
- MK0476, montelukast sodium / Duration of Treatment: 8 Weeks
- Volunteers
- 198 people
- Sponsor
- Organon and Co
Asthma
Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363)
Evaluation of treatment in participants with mild asthma.
- Trial name
- NCT00688467
- Testing
- Navarixin
- Volunteers
- 19 people
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001
The purpose of this study is to evaluate the amount of the study drug, CHF6001, in the blood of adolescent patients with asthma in comparison to adult patients with asthma after a single oral dose of the study drug, CHF 6001.
- Trial name
- NCT06900816
- Testing
- CHF 6001
- Where
- Bulgaria
- Volunteers
- 50 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
Long-term Safety Study for GSK573719 in Japanese
The objective of this study is to evaluate the safety and tolerability of GSK573719 Inhalation Powder 125 mcg once-daily over 52 weeks in Japanese subjects with COPD.
- Trial name
- AC4115361 (NCT01702363)
- Testing
- GSK573719
- Where
- 20 sites in Japan
- Volunteers
- 131 people
- Sponsor
- GlaxoSmithKline
Asthma
Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects
This is a randomized, placebo-controlled, 2-period crossover, escalating repeat dose study, aiming to investigate whether higher potency of different inhaled corticosteroid confers an improvement in the topical efficacy to…
- Trial name
- NCT02991859
- Testing
- Fluticasone furoate (FF) Dry Powder Inhaler, Fluticasone propionate (FP) Dry Powder Inhaler, Budesonide (BUD) Turbuhaler
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Bronchiolitis Obliterans Syndrome
A Retrospective Chart Review Study of Patients With CLAD-BOS Post Lung Transplantation
The Primary Objective of this study was to evaluate the FEV1 trajectory of patients diagnosed with CLAD-BOS. The Secondary Objectives of this study were: To describe demographics of patients diagnosed with CLAD-BOS To describe…
- Trial name
- NCT06503770
- Where
- 6 sites in United States, Belgium and 1 more
- Volunteers
- 284 people
- Sponsor
- Zambon SpA